GlaxoSmithKline Pharmaceuticals

₹2,540As of Sun 8 Nov 2026, 12:00 UTC

NSE:GLAXOHealthcare

Country India

PE (Fwd) 40.58

TSR 10Y CAGR 7.98%

Div yield 2.24%

ROE —

Drug Manufacturers (General)

Beta (5Y) 0.17

PE TTM 41.53

TSR TTM (0.55%)

Mkt cap ₹459.0B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹2,750

8.28%

(80.27%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

38.22

Revenue₹B

—

32.78

32.52

34.54

37.49

38.22

39.76

3.91%

1.93

Revenue growth%

—

(0.80)

6.21

8.56

1.93

4.05

4.07

—

64.00

Gross margin%

—

57.96

59.89

60.76

62.29

64.00

64.07

60.76

32.64

Operating margin%

—

21.32

23.02

24.29

29.72

32.64

32.70

24.29

27.11

Net margin%

—

51.70

18.78

17.08

24.74

27.11

26.08

24.74

41.53

P/E ratio (avg)x

—

15.94

38.57

52.74

46.10

47.49

41.49

46.10

34.48

EV/EBITx

—

38.65

31.47

37.08

38.37

39.44

33.09

38.37

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

61.15

EPS₹

—

100.04

36.05

34.83

54.76

61.15

61.21

(11.58%)

—

11.69

EPS growth%

—

(63.97)

(3.39)

57.23

11.69

0.10

4.15

—

Bookvalue per sh₹

—

FCF per share₹

—

57.00

Dividend per sh₹

—

30.00

32.00

42.00

57.00

61.31

17.41%

—

2.24

Div yield (avg)%

—

1.88

2.30

1.74

1.66

1.96

2.41

1.88

93.21

Payout ratio%

—

29.99

88.77

91.89

76.71

93.21

100.16

88.77

169.4

Shares (diluted)M

—

169.4

◌169.4

—

Buyback yield%

—

◌—

—

D/E ratiox

—

430.2

Enterprise value₹B

—

270.1

235.6

311.1

427.6

492.0

430.2

16.17%

—

LT debt₹M

—

Peers (US$4.564B)

Cap (US$)

Rubicon Research…

2.925B

85.29x

Pfizer Limited

1.879B

20.53x

CORONA Remedies Limited

1.590B

72.12x

Santen Pharmaceutical…

3.862B

15.70x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

456.6

Own earn%

—

Sh yield%

2.24

1.85

Owners

Insiders/Inst%

—

11.60

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

21–33

$1 testx

—

Incr. ROIC%

—

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹38.22B

3.91%

1.00×

Cost of revenue

₹13.76B

(0.05%)

0.86×

Operating expenses

₹11.98B

(0.05%)

0.86×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m